38 results found.

Sickle Cell Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Measurement of the Reactive Hyperemia Index in Sickle Cell Patients During Pain Crisis and After Recovery.

Sickle Cell Disease Clinical Trial using SelG1; Placebo

Selexys Pharmaceuticals Corporation - Recruiting 16 years to 65 years.
- A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises.
SelG1; Placebo

Sickle Cell Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Microvascular and Cardiac Dysfunction in Sickle Cell Disease.

Sickle Cell Disease Clinical Trial using Prasugrel; Placebo

Eli Lilly and Company - Recruiting 2 years to 17 years.
- A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease..
Prasugrel; Placebo

Transfusional Iron Overload, Thalassemia Major, Sickle Cell Disea Clinical Trial using Hepatic biomagnetic susceptibility measurement

Columbia University - Recruiting 5 years to 80 years.
- High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device).
Hepatic biomagnetic susceptibility measurement

Sickle Cell Disease Clinical Trial using NiCord

Gamida Cell ltd - Recruiting 2 years to 21 years.
- Allogeneic Stem Cell Transplantation of NiCordr, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease.
NiCord

Vaso-occlusive Crisis, or Sickle Cell Disease Clinical Trial using MST-188; Saline

Mast Therapeutics, Inc. - Recruiting 4 years to 65 years.
- Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis.
MST-188; Saline

Genotype, Pain, Sickle Cell Anemia, or Vaso-Occlusive Pain Crisis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Exploratory Studies of Psychophysical Pain Phenotyping and Genetic Variability in Sickle Cell Disease.

Bone Marrow Transplant, or Sickle Cell Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 8 years or older.
- Screening of Subjects to Determine Eligibility to Safely Participate in Blood Disorders Studies.

Healthy, or Sickle Cell Anemia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 45 years.
- Collection and Storage of Umbilical Cord Hematopoietic Stem Cells for Sickle Cell Disease Therapy.

Congenital Hemolytic Anemia, or Diamond-Blackfan Anemia Clinical Trial using Radiotherapy; Alemtuzumab (Campath ); Sirolimus (Rapamune )

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 65 years.
- Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease, Thalassemia, and Diamond Blackfan Anemia.
Radiotherapy; Alemtuzumab (Campath ); Sirolimus (Rapamune )

Sickle Cell Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Evaluation of Sickle Cell Liver Disease.

Sickle Cell Trait, or Sickle Cell Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 8 years or older.
- High Throughput Screening of Compound Libraries to Discover a Drug for the Treatment of Sickle Cell Disease.

Sickle Cell Disease Clinical Trial using Oral Decitabine and Tetrahydrouridine; Placebo

The Cleveland Clinic - Recruiting 18 years or older.
- Phase 1 Study of Oral Decitabine and Tetrahydrouridine (THU) in Patients With High Risk Sickle Cell Disease.
Oral Decitabine and Tetrahydrouridine; Placebo

Peripheral Blood Stem Cell Transplantation, Anemia, Sickle Cell, Clinical Trial using PBMC Transplant; Alemtuzumab (Campath ); Sirolimus (Rapamune ); Cyclophosphamide (Cytoxan ); Low Dose Irradiation

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia.
PBMC Transplant; Alemtuzumab (Campath ); Sirolimus (Rapamune ); Cyclophosphamide (Cytoxan ); Low Dose Irradiation

Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, or Sickle C Clinical Trial using Fludarabine; Cytarabine; Cellular Infusions; Total Body Irradiation; Cyclophosphamide; Bortezomib; Rituximab; Plasmapheresis

Thomas Jefferson University - Recruiting 18 years to 45 years.
- Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia From HLA Matched or Partially-Matched Related Donors.
Fludarabine; Cytarabine; Cellular Infusions; Total Body Irradiation; Cyclophosphamide; Bortezomib; Rituximab; Plasmapheresis

Sickle Cell Disease Clinical Trial using Alemtuzumab; Fludarabine; Melphalan

Hackensack University Medical Center - Recruiting 2 years to 30 years.
- Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old.
Alemtuzumab; Fludarabine; Melphalan

Sickle Cell Disease Clinical Trial using Hydroxyurea

Baylor College of Medicine - Recruiting 1 year to 16 years.
- NOVEL DOSE PREDICTION FOR TREATMENT WITH HYDROXYUREA (NDEPTH).
Hydroxyurea

Hemoglobin SC Disease, Hematologic Diseases, Sickle Cell Anemia, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 5 years or older.
- Studies of the Natural History of Sickle Cell Disease and Other Hemolytic Disorders.

Sickle Cell Disease, Sickle Cell Anemia, or Anemia, Sickle Cell Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- End-Alveolar Carbon Monoxide as a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease.

Neutropenia, Sickle Cell Disease, Decitabine, or Fetal Hemoglobin Clinical Trial using Decitabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- An Extended Phase II Study of Decitabine in Subjects With High Risk Sickle Cell Disease.
Decitabine

Sickle Cell Disease and Thalassemia Clinical Trial using Donor Stem Cell Transplantation

University of Texas Southwestern Medical Center - Recruiting 18 years to 45 years.
- Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Thalassemia.
Donor Stem Cell Transplantation

Sickle Cell Disease Clinical Trial using Community Health Worker (CHW); Education

Columbia University - Recruiting 10 years to 18 years.
- Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT.
Community Health Worker (CHW); Education

Sickle Cell Disease Clinical Trial using Haploidentical Transplant; Alemtuzumab; Total Body Irradiation; Cyclophosphamide; Sirolimus

University of Illinois at Chicago - Recruiting 16 years to 60 years.
- SCD-Haplo: A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease.
Haploidentical Transplant; Alemtuzumab; Total Body Irradiation; Cyclophosphamide; Sirolimus

Sickle Cell Anemia Clinical Trial

St. Jude Children's Research Hospital - Recruiting 5 years to 19 years.
- State Of The Art Functional Imaging In Sickle Cell Disease.

Sickle Cell Disease Clinical Trial using Brigance Preschool Screen -II

St. Jude Children's Research Hospital - Recruiting 3 years to 4 years.
- The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2.
Brigance Preschool Screen -II

Sickle Cell Disease Clinical Trial using Assessment

St. Jude Children's Research Hospital - Recruiting 12 years to 30 years.
- Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program.
Assessment

Autoimmune Diseases, Sickle Cell Disease, or Chronic Graft Versus Clinical Trial using Acoustic Radiation Force Impulse (ARFI); Laser Doppler Flowmetry (LDF); Laser Doppler Perfusion Imaging (LDI); Optical Coherence Tomography (OCT); Orthogonal Polarization Spectral Imaging (OPSI); Nail fold video capillaroscopy (NVC)

Duke University - Recruiting 18 years or older.
- Mechanistic Study: Non-Invasive Cutaneous Microvascular and Fibrosis Imaging of Patients With Systemic Sclerosis, Sickle Cell Disease and Chronic Graft-Versus-Host Disease (GVHD) Compared to Healthy Subjects.
Acoustic Radiation Force Impulse (ARFI); Laser Doppler Flowmetry (LDF); Laser Doppler Perfusion Imaging (LDI); Optical Coherence Tomography (OCT); Orthogonal Polarization Spectral Imaging (OPSI); Nail fold video capillaroscopy (NVC)

Sickle Cell Disease Clinical Trial using G-CSF; cyclophosphamide; fludarabine phosphate; mycophenolate mofetil; Sirolimus; Allogeneic bone marrow transplantation; total-body irradiation; Levetiracetam

Sidney Kimmel Comprehensive Cancer Center - Recruiting 2 years to 70 years.
- A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Anemia and Other Hemoglobinopathies.
G-CSF; cyclophosphamide; fludarabine phosphate; mycophenolate mofetil; Sirolimus; Allogeneic bone marrow transplantation; total-body irradiation; Levetiracetam

Sickle Cell Disease Clinical Trial

St. Jude Children's Research Hospital - Recruiting N/A to 30 years.
- Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease.

Sickle Cell Disease Clinical Trial using NKTT120

NKT Therapeutics - Recruiting 18 years to 60 years.
- A Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of Intravenous NKTT120 in Adults With Stable Sickle Cell Disease.
NKTT120

Thalassemia, Sickle Cell Disease, or Myelodysplasia Clinical Trial using Blood sample

Assistance Publique - H“pitaux de Paris - Recruiting 6 years or older.
- Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations.
Blood sample

Thalassemia, or Sickle Cell Disease Clinical Trial using Medical Chart Summary

HaEmek Medical Center, Israel - Recruiting 5 years to 45 years.
- Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia.
Medical Chart Summary

Sickle Cell Disease, or Sickle Cell Anemia Clinical Trial using regadenoson infusion with contrast-enhanced ultrasound; contrast-enhanced ultrasound

Blood Center of Wisconsin - Recruiting 18 years to 70 years.
- Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia.
regadenoson infusion with contrast-enhanced ultrasound; contrast-enhanced ultrasound

Sickle Cell Disease Clinical Trial using MRI, Transthoracic Echocardiography, tonometry, EKG

University of Chicago - Recruiting 18 years or older.
- Cardiovascular Complications of Sickle Cell Disease.
MRI, Transthoracic Echocardiography, tonometry, EKG

Sickle Cell Disease Clinical Trial

Children's Hospital Los Angeles - Recruiting 13 years or older.
- Iron-mediated Vascular Disease in Sickle Cell Disease..

Rheologic Disease, Sickle Cell Disease, or Paroxysmal Nocturnal H Clinical Trial using Imaging

Oregon Health and Science University - Recruiting 19 years or older.
- Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease.
Imaging

Anemia, Sickle Cell, or Transfusion Hemochromatosis Clinical Trial using deferasirox

Children's Hospital Los Angeles - Recruiting 14 years or older.
- Clinical Importance of Treating Iron Overload in Sickle Cell Disease.
deferasirox